- Packaged-food companies including Conagra are running behavioral science experiments in test kitchens to understand how to make smaller-portion foods feel more satisfying to GLP-1 users, whose drug-suppressed appetites mean they eat less volume but still respond to sensory cues — texture, richness, aroma — that signal satiety to the brain even when caloric intake is significantly reduced.
- The urgency is financial: GLP-1 drugs like Wegovy and Ozempic, now taken by tens of millions of Americans and expanding rapidly, are structurally threatening the high-volume, calorie-dense packaged food categories that have generated billions in annual revenue — chips, frozen meals, snacks, and convenience foods designed for consumers who eat until full, not consumers who stop eating after a few bites.
- The behavioral science challenge is more nuanced than simply shrinking portions: GLP-1 users report changes in food preferences beyond just quantity, including reduced cravings for ultra-processed, high-fat, and high-sugar foods — meaning food companies cannot simply sell smaller bags of the same products, but may need to fundamentally reformulate flavors, textures, and ingredient profiles to match a neurologically altered palate.
- The GLP-1 disruption is accelerating an existing trend of consumer migration away from ultra-processed foods, and food companies that fail to adapt risk a structural demand decline rather than a cyclical one — making the test kitchen investments at companies like Conagra less a product development exercise and more an existential strategic pivot to remain relevant in a market where the consumer’s relationship with food is being pharmacologically transformed.
What Happened?
Inside a test kitchen in Omaha, Conagra executives gathered around trays of microwaved eggs, potatoes, sausage, and cheese sauce — not for a product launch, but for a behavioral science exercise led by Ashley Lind, the company’s head of behavior science. The question she was studying: what makes food feel satisfying when you’re not actually very hungry? The session is part of a broader industry-wide effort by packaged-food makers to understand and adapt to the GLP-1 era, in which tens of millions of consumers are taking semaglutide, tirzepatide, and related drugs that significantly suppress appetite and alter food cravings. For Conagra and its peers — whose business models are built on selling high volumes of calorie-dense convenience foods — the rise of GLP-1 drugs represents one of the most significant demand disruptions the industry has ever faced.
Why It Matters?
The packaged food industry has navigated decades of health trends — low-fat, low-carb, organic, plant-based — without fundamental disruption because those trends were driven by consumer choice and typically led to product-line extensions rather than demand destruction. GLP-1 drugs are different: they operate on the neurology of appetite itself, mechanically reducing the drive to eat rather than asking consumers to consciously eat less. That distinction matters enormously for food companies. A consumer who is dieting by willpower still craves chips and frozen meals even if they resist them. A consumer on Wegovy may simply stop craving those products at all. Novo Nordisk’s own low-dose trial data and real-world prescribing patterns suggest GLP-1 adoption is moving rapidly down the BMI curve, toward overweight rather than obese patients — which means the addressable population of neurologically altered food consumers is far larger than current prescription volumes suggest.
What’s Next?
Food companies face a multi-year reformulation cycle with uncertain endpoints. The most immediate adaptation is portion-size optimization — smaller packages and serving sizes that reduce waste and match GLP-1 users’ reduced intake without changing the underlying product. The deeper challenge is flavor and texture reformulation for a palate that research suggests shifts toward less sweet, less fatty, and more protein-forward preferences under GLP-1 influence. Companies that crack the formula for “satisfying in small amounts” — dense nutrition, high satiety-signal texture, clean flavor payoff — will be positioned to capture GLP-1 users as a distinct consumer segment. Those that don’t risk watching their core consumers permanently migrate to fresh, minimally processed foods. The Conagra test kitchen sessions represent early-stage sensing of a problem that will likely define the packaged food industry’s strategic agenda for the rest of the decade.
Source: The Wall Street Journal
